Linkedin
RLS logo_header
Linkedin

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for ADCs

“ADCs represent one of the most promising and fast-growing modalities for new biopharmaceuticals. We’re honored to be among a select group collaborating with the FDA to help shape regulatory standards for ADC development and quality control,” said Hans-Peter Gerber, Ph.D., Sutro’s Chief Scientific Officer. “This collaboration underscores the precision and flexibility of our cell-free XpressCF® platform in advancing next-generation ADCs, and we look forward to the impact of this work across the industry, with regulators, and for the patient community. We thank the FDA for the opportunity to help define the future of ADC innovation.”

Read the full story on "Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for ADCs"

Share:

More News

TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors

“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer

“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in

Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers

“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of

First Patient Dosed in Ph 1/2 Study of MT-304 in HER2-Positive Solid Tumors

Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo